Patriciu Achimas Cadariu
Overview
Explore the profile of Patriciu Achimas Cadariu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Covaliu B, Forray A, Tomic M, Vlad C, Cadariu P, Ungurean C, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002299
: Cervical cancer causes high mortality rates globally despite the existence of cervical cancer screening. The purpose of this study is to investigate the factors limiting Romanian women's participation in...
2.
Popita A, Rusu A, Muntean V, Cadariu P, Irimie A, Lisencu C, et al.
Med Pharm Rep
. 2023 Aug;
96(3):258-268.
PMID: 37577010
Background And Aims: To evaluate the performance of magnetic resonance imaging (MRI) in restaging locally advanced rectal cancers (LARC) after neoadjuvant chemoradiotherapy (nCRT), with pathologic correlation. Methods: 80 patients with...
3.
Petrut B, Bujoreanu C, Porav Hodade D, Hardo V, Coste B, Maghiar T, et al.
J BUON
. 2021 Mar;
26(1):266-274.
PMID: 33721461
Purpose: Indocyanine green (ICG) is being used more and more in Urology along with advances in minimal invasive surgery, guiding excision and reconstruction, highlighting anatomic structures and functional features with...
4.
Munteanu V, Munteanu R, Gulei D, Schitcu V, Petrut B, Berindan Neagoe I, et al.
Diagnostics (Basel)
. 2020 Oct;
10(10).
PMID: 33050493
Prostate cancer represents the most encountered urinary malignancy in males over 50 years old, and the second most diagnosed after lung cancer globally. Digital rectal examination and prostatic specific antigen...
5.
Kubelac P, Craciun A, Jalba O, Gheorghe S, Lazar G, Ignat F, et al.
J BUON
. 2020 Aug;
25(3):1658-1663.
PMID: 32862619
Purpose: The purpose of this study was to evaluate the predictive performance of OncoOVARIAN Dx algorithm, which takes into account tumor markers (beta HCG, CA 19.9, CEA, AFP, CA 125,...
6.
Bochis O, Vlad C, Cainap C, Cadariu P, Sur D, Havasi A, et al.
J BUON
. 2020 Jun;
25(2):875-883.
PMID: 32521881
Purpose: Bevacizumab or cetuximab represent the standard treatment in association with classical chemotherapy in confirmed metastatic colorectal cancer (mCRC). Bevacizumab could be continued after the first disease progression with an...
7.
Kubelac P, Vlad C, Berindan Neagoe I, Irimie A, Cadariu P
J BUON
. 2019 Oct;
24(4):1538-1543.
PMID: 31646805
Purpose: The treatment of ovarian cancer continues to pose a challenge especially through the development of platinum-resistant disease and still has the highest mortality rate among gynecologic cancers. Patients are...
8.
Onisim A, Vlad C, Simon I, Dina C, Cadariu P
J BUON
. 2019 Aug;
24(3):1009-1019.
PMID: 31424655
Purpose: The heterogeneous phenotype of epithelial ovarian cancer (EOC) explains the unpredictable behaviour in terms of response to therapy, time to progression and survival. In this context, CD146, a cell...
9.
Onisim A, Cadariu P, Iancu M, Puscas E, Bodog A, Vlad C
J BUON
. 2019 Aug;
24(3):982-989.
PMID: 31424651
Purpose: Ovarian cancer has the poorest survival rate among gynaecological malignancies. Besides the comparison of different therapeutic strategies aimed to improve outcomes, studies have also begun to focus on aspects...
10.
Bonci E, Buiga R, Badan M, Iuliana Maja L, Gata V, Lisencu I, et al.
J BUON
. 2019 Jan;
23(6):1912-1921.
PMID: 30610821
Purpose: In recent studies, follicle-stimulating hormone receptors (FSHRs) have been reported in a wide range of malignant and benign tumours, depending on the type of antibody used. Using two commercially...